Beovu
Chemical Name | brolucizumab–dbll |
Dosage Form | Injectable (intravitreal; 6 mg/0.05 mL) |
Drug Class | Monoclonal antibodies |
System | Ocular |
Company | Novartis |
Approval Year | 2019 |
Indication
- Beovu is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD).